Satsuma Pharmaceuticals, Inc. (“Satsuma”, San Francisco, CA, USA) was established in June 2016 with the purpose of globally expanding the Translational Research business of Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) by developing migraine therapeutics¹⁾ consisting of dihydroergotamine (“DHE”) and SNBL’s novel nasal delivery technology, STS101.

Satsuma has reported its financial and business results for the first quarter of 2020. Satsuma anticipates no significant delays in STS101 development program timelines. Satsuma is continuing randomization and treatment of patients in the ongoing EMERGE^TM Phase 3 efficacy trial of STS101 and anticipates topline data in the second half of 2020.

Also, Satsuma has reported it to be well-capitalized with cash, cash equivalents, and marketable securities totaling $104.1 million at the end of Q1 2020 providing runway through planned STS101 NDA filing by year-end 2021.

For more information, please visit Satsuma’s press release.

1) About migraine

There are currently an estimated 39 million people in the U.S., suffering from migraine headaches, and the market for migraine therapeutics is reported to have reached $16 billion in 2017 in the US alone. A large number of patients are relatively young, between 20 and 40 years old, and there is an existing need for quick relief of potentially-disabling headaches. DHE is effective for non-responders of triptans, which are currently first-in-line therapies; however, the current liquid nasal spray is slow to absorb, taking at least 30 minutes to take effect, and the product is regarded to be unreliable due to its variability in absorption and the relatively low blood concentrations it achieves. The Nasal DHE product using SNBL's nasal delivery technology enables fast and adequate absorption and is expected to meet the needs of patients.